CXCL5 limits macrophage foam cell formation in atherosclerosis

Anthony Rousselle,1 Fatimunnisa Qadri,1 Lisa Leukel,1 Rüstem Yilmaz,1 Jean-Fred Fontaine,1 Gabin Sihn,1 Michael Bader,1 Amrita Ahluwalia,2 and Johan Duchene1

1Max Delbrück Center for Molecular Medicine, Berlin, Germany. 2William Harvey Research Institute, Queen Mary, University of London, Barts and The London, London, United Kingdom.

The ELR+–CXCL chemokines have been described typically as potent chemoattractants and activators of neutrophils during the acute phase of inflammation. Their role in atherosclerosis, a chronic inflammatory vascular disease, has been largely unexplored. Using a mouse model of atherosclerosis, we found that CXCL5 expression was upregulated during disease progression, both locally and systemically, but was not associated with neutrophil infiltration. Unexpectedly, inhibition of CXCL5 was not beneficial but rather induced a significant macrophage foam cell accumulation in murine atherosclerotic plaques. Additionally, we demonstrated that CXCL5 modulated macrophage activation, increased expression of the cholesterol efflux regulatory protein ABCA1, and enhanced cholesterol efflux activity in macrophages. These findings reveal a protective role for CXCL5, in the context of atherosclerosis, centered on the regulation of macrophage foam cell formation.

Introduction

Atherosclerosis is a disease in which chronic inflammation plays a fundamental role. Activated macrophages accumulate in atherosclerotic lesions and contribute not only to the initiation phase but also to the development, progression, and the complication stages of the disease (1). Chemokines, cytokines that attract and activate leukocytes, are implicated in all stages of atherosclerosis and as such have been proposed as potential therapeutic targets (2). Substantial evidence has incriminated the CCL2 and CX3CL1 chemokines, which recruit and stimulate monocytes/macrophages, in the pathogenesis of atherosclerosis (1).

Although it is known that ELR+–CXCL chemokines, in particular CXCL1 and CXCL2, are induced during atherosclerosis (3–5), their exact functional contribution to the development of the pathology has not been ascertained. Indeed, while the ELR+–CXCL chemokines have been identified as potent and specific attractants of neutrophils in acute inflammation (2), whether this effect underlies their role in chronic diseases such as atherosclerosis is uncertain. One study, however, has put forward the hypothesis that the ELR+–CXCL receptor CXCR2 is involved in the accumulation of macrophages in advanced atherosclerotic plaques leading to lesion progression (6). The fact that CXCL1 alone has a similar but less pronounced effect (7) points toward the implication of alternative CXCR2 ligands in the pathogenesis of atherosclerosis. However, CXCL5, which has recently been shown to participate in foam macrophage accumulation, and atherosclerotic plaque formation. This intimates that CXCL5 comes from endothelial cells rather than the atheromatous plaque. Accordingly, activated macrophages and cholesterol-loaded macrophages in vitro did not produce CXCL5 (data not shown). In human endothelial cells, in which the combinatory treatment of oxidized LDL or IL-1β and proatherogenic (low) laminar shear stress (LSS) leads to a similar dysfunction, an increase of expression of the human homolog of CXCL5, CXCL6 (9), was seen compared with that in endothelial cells subjected to physiological (high) LSS (Figure 1, E–G). The expression of CXCL8, the alleged ELR+–CXCL prototype chemokine in humans, remained unchanged (Figure 1, E and F).

Inhibition of CXCL5 is associated with macrophage foam cell accumulation in atherosclerotic plaques. Despite the potent neutrophil chemotaxis of

Endothelial cells are a source of CXCL5 in atherogenic conditions. Similar to what we observed in Apoe−/− mice, there was an increase of CXCL5 expression in the aortas of WT animals treated with a WD (Figure 1D), a mouse model that develops mild hypercholesterolemia-induced endothelial dysfunction but without monocyte infiltration, foam macrophage accumulation, and atherosclerotic plaque formation. This intimates that CXCL5 comes from endothelial cells rather than the atheromatous plaque. Accordingly, activated macrophages and cholesterol-loaded macrophages in vitro did not produce CXCL5 (data not shown). In human endothelial cells, in which the combinatory treatment of oxidized LDL or IL-1β and proatherogenic (low) laminar shear stress (LSS) leads to a similar dysfunction, an increase of expression of the human homolog of CXCL5, CXCL6 (9), was seen compared with that in endothelial cells subjected to physiological (high) LSS (Figure 1, E–G). The expression of CXCL8, the alleged ELR+–CXCL prototype chemokine in humans, remained unchanged (Figure 1, E and F).

Inhibition of CXCL5 is associated with macrophage foam cell accumulation in atherosclerotic plaques. Despite the potent neutrophil chemotaxis of

Results and Discussion

Uproregulation of CXCL5 in atherosclerosis. In atherosclerosis-prone Apoe−/− mice fed a Western diet (WD), CXCL5 expression was upregulated in both aorta and plasma and remained elevated up to 48 weeks (Figure 1A). As previously observed (3, 5), expression of CXCL1 and CXCL2 was also increased as disease progressed (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI66580DS1). This rise in CXCL5 expression, unlike the rise in CXCL1 and CXCL2, was also evident in Apoe−/− mice fed a chow diet (CD) for 12 weeks (Figure 1, B and C), despite a lower elevation of plasma triglycerides and cholesterol levels (Supplemental Figure 1B). Of note, the level of CXCL5 induction (mRNA and protein) was similar with both diets in Apoe−/− mice, which suggests that CXCL5 expression is induced once the cholesterol levels reach a mild hypercholesterolemia but is not further increased if the cholesterol level goes above this threshold. Further analysis of the aortic arch region, which is more prone to develop atherosclerotic plaques, compared with the thoracic aortas of Apoe−/− mice fed a CD, confirmed that CXCL5, but not CXCL1 and CXCL2, expression was specifically upregulated in susceptible regions (9-fold increase) (Supplemental Figure 1C). These data suggest that the regulation of CXCL5 expression is distinct from that of CXCL1 and CXCL2 and that CXCL5 might play an essential role in atherosclerosis.

Inhibition of CXCL5 is associated with macrophage foam cell accumulation in atherosclerotic plaques. Despite the potent neutrophil chemotaxis of
CXCL5 in acute inflammatory models (2, 10, 11), the rise in CXCL5 levels observed in Apoe–/– mice fed a WD was not accompanied by neutrophil infiltration within the atheromatous plaques (Supplemental Figure 1D). Moreover, blocking CXCL5 using a specific mAb did not diminish lesion size (Supplemental Figure 2, A and B) or the infiltration of monocytes/macrophages (Figure 2, E, G, and I, and Supplemental Figure 2C), as has been observed when blocking CXCL1 and CXCR2 in murine models of atherosclerosis (6, 7). Instead, we observed an accumulation of foam cells in both the brachiocephalic artery and the aortic root lesions (Figure 2B and Supplemental Figure 2E) corresponding to macrophages (Figure 2, C, E, G, and I, and Supplemental Figure 2C) with increased lipid storage capacity (Figure 2, C, F, H, and J, and Supplemental Figure 2D). This was accompanied by a significant reduction of collagen content (Figure 2, A and D, and Supplemental Figure 2, E and F), suggesting a role for CXCL5 in both macrophage activity and plaque stability. The kinin B1 receptor has been recently described to regulate CXCL5 expression (10). This specific CXCL5 reduction also could be observed in ApoE-B1R double-knockout mice (Supplemental Figure 3A) and was associated with higher macrophage foam cell accumulation in atherosclerotic plaques (Supplemental Figure 3, D–G). These observations corroborate the role of CXCL5 in atherosclerosis, without the use of blocking Abs, and in a more chronic state with mild hypercholesterolemia (after 60 weeks of CD). However, neither of the 2 models had a change in monocytes or plasma cholesterol levels (Table 1 and Supplemental Figure 3, B and C), suggesting that CXCL5 limits macrophage foam cell accumulation through a different route. In the context of CXCL5 inhibition, it was recently described that a subsequential increase of CXCL1 and CXCL2 as well as their upstream regulator IL-17 could lead to a greater recruitment of leukocytes or leukocytosis (11, 12). Moreover, CXCL1 and CXCL2 have both been implicated in leukocyte mobilization (13, 14) and CXCL1 has been implicated as a potent monocyte chemoattractant in atherosclerosis (15). However, this indirect effect could not account for our results, since neither expression levels of CXCL1, CXCL2, and IL-17 nor monocytosis were affected here (Table 1, Supplemental Figure 3A, and Supplemental Figure 5). Importantly, we demonstrated that exogenous CXCL5 diminished peritoneal macrophage (PM) foam cell formation in vivo (Figure 3A and Supplemental Figure 4). Taken together, these findings intimate that CXCL5 can alter the phenotype of macrophages in atherosclerosis by preventing foam cell formation.

**CXCL5 regulates macrophage activation.** It is well described that the T cell–adaptive response participates in atherogenesis (1). Because T cells are known to modulate macrophages, we asked whether

**Table 1**  
Anti-CXCL5 Ab does not change peripheral blood parameters in Apoe–/– mice

<table>
<thead>
<tr>
<th>Models</th>
<th>Total cholesterol (mg/dl)</th>
<th>Monocytes (% of wbc)</th>
<th>CXCL1 (pg/ml)</th>
<th>CXCL2 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isotype IgG</td>
<td>739.2 ± 62.4</td>
<td>7.2 ± 0.7</td>
<td>1,154 ± 104</td>
<td>103 ± 24</td>
</tr>
<tr>
<td>CXCL5 Ab</td>
<td>840.1 ± 133.9</td>
<td>6.9 ± 0.4</td>
<td>1,033 ± 88</td>
<td>107 ± 12</td>
</tr>
</tbody>
</table>

CXCL5 in acute inflammatory models (2, 10, 11), the rise in CXCL5 levels observed in Apoe–/– mice fed a WD was not accompanied by neutrophil infiltration within the atheromatous plaques (Supplemental Figure 1D). Moreover, blocking CXCL5 using a specific mAb did not diminish lesion size (Supplemental Figure 2, A and B) or the infiltration of monocytes/macrophages (Figure 2, E, G, and I, and Supplemental Figure 2C), as has been observed when blocking CXCL1 and CXCR2 in murine models of atherosclerosis (6, 7). Instead, we observed an accumulation of foam cells in both the brachiocephalic artery and the aortic root lesions (Figure 2B and Supplemental Figure 2E) corresponding to macrophages (Figure 2, C, E, G, and I, and Supplemental Figure 2C) with increased lipid storage capacity (Figure 2, C, F, H, and J, and Supplemental Figure 2D). This was accompanied by a significant reduction of collagen content (Figure 2, A and D, and Supplemental Figure 2, E and F), suggesting a role for CXCL5 in both macrophage activity and plaque stability. The kinin B1 receptor has been recently described to regulate CXCL5 expression (10). This specific CXCL5 reduction also could be observed in ApoE-B1R double-knockout mice (Supplemental Figure 3A) and was associated with higher macrophage foam cell accumulation in atherosclerotic plaques (Supplemental Figure 3, D–G). These observations corroborate the role of CXCL5 in atherosclerosis, without the use of blocking Abs, and in a more chronic state with mild hypercholesterolemia (after 60 weeks of CD). However, neither of the 2 models had a change in monocytes or plasma cholesterol levels (Table 1 and Supplemental Figure 3, B and C), suggesting that CXCL5 limits macrophage foam cell accumulation through a different route. In the context of CXCL5 inhibition, it was recently described that a subsequential increase of CXCL1 and CXCL2 as well as their upstream regulator IL-17 could lead to a greater recruitment of leukocytes or leukocytosis (11, 12). Moreover, CXCL1 and CXCL2 have both been implicated in leukocyte mobilization (13, 14) and CXCL1 has been implicated as a potent monocyte chemoattractant in atherosclerosis (15). However, this indirect effect could not account for our results, since neither expression levels of CXCL1, CXCL2, and IL-17 nor monocytosis were affected here (Table 1, Supplemental Figure 3A, and Supplemental Figure 5). Importantly, we demonstrated that exogenous CXCL5 diminished peritoneal macrophage (PM) foam cell formation in vivo (Figure 3A and Supplemental Figure 4). Taken together, these findings intimate that CXCL5 can alter the phenotype of macrophages in atherosclerosis by preventing foam cell formation.

**CXCL5 regulates macrophage activation.** It is well described that the T cell–adaptive response participates in atherogenesis (1). Because T cells are known to modulate macrophages, we asked whether

**Table 1**  
Anti-CXCL5 Ab does not change peripheral blood parameters in Apoe–/– mice

<table>
<thead>
<tr>
<th>Models</th>
<th>Total cholesterol (mg/dl)</th>
<th>Monocytes (% of wbc)</th>
<th>CXCL1 (pg/ml)</th>
<th>CXCL2 (pg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isotype IgG</td>
<td>739.2 ± 62.4</td>
<td>7.2 ± 0.7</td>
<td>1,154 ± 104</td>
<td>103 ± 24</td>
</tr>
<tr>
<td>CXCL5 Ab</td>
<td>840.1 ± 133.9</td>
<td>6.9 ± 0.4</td>
<td>1,033 ± 88</td>
<td>107 ± 12</td>
</tr>
</tbody>
</table>
blocking CXCL5 in atherosclerotic mice could have affected the overall profile of cytokines typically secreted by T cells. Plasma levels of cytokines produced by Th1 (IFN-γ and IL-2), Th2 (IL-4), Th17 (IL-17), or Treg (IL-10) cells were unchanged (Supplemental Figure 5). However, circulating levels of IL-6, a cytokine mainly secreted by activated macrophages, were significantly lower in Apoe–/– mice treated with anti-CXCL5 Ab (Figure 2K). In addition, a gene expression correlation analysis, based upon a microarray data set of age-dependent aorta transcriptomes from WT and Apoe–/– mice, revealed that among all cytokines only IL-6 was positively and highly correlated with CXCL5 profile expression \((r = 0.76)\) (Supplemental Table 1). Moreover, a biological functions analysis of these correlated genes revealed that, besides the expected immune function genes, the expression of CXCL5 in atherosclerosis was particularly associated with macrophage activation genes (Supplemental Table 2, \(P = 1.47 \times 10^{-7}\)). These observations strongly suggest that CXCL5 directly acts on macrophages rather than on the T cell-adaptive response. Indeed, stimulation of primary bone marrow–derived macrophages (BMDMs) and PMs with CXCL5 induced an augmentation of \(Il6\) expression, an effect that was even greater in cholesterol-loaded macrophages (Figure 3B and Supplemental Figure 6, B and C). Thus, in addition to the well-described neutrophil arrest and recruitment-associated functions of ELR–CXCL chemokines, herein we demonstrate that CXCL5 specifically modulates macrophage activation, particularly by upregulating IL-6 expression.

**Activation of the CXCL5/CXCR2 pathway induces ABCA1 expression and cholesterol efflux in macrophages.** Since in our experiments the primary target of CXCL5 appeared to be macrophages, we investigated whether the effects of CXCL5 on foam cell formation observed in vivo were due to a direct action. In vitro, CXCL5 was indeed able to reduce intracellular lipid accumulation in macrophages (Figure 3C). We speculated that this might be attributable to a decrease of cholesterol uptake or/and an increase of cholesterol efflux. In BMDMs and PMs, CXCL5 treatment significantly upregulated the expression of \(Aba1\), a transporter that mediates the efflux of cholesterol (Figure 3, D and E, and Supplemental Figure 6D). In contrast, the expression of other cholesterol trafficking genes, such as
as Mr1, Cd36, and Abcg1, was not affected. Accordingly, in the in vivo gene expression correlation study mentioned earlier, Abca1 was highly correlated with CXCL5 expression (r = 0.78, Supplemental Table 1). ABCA1 upregulation was even more pronounced in cholesterol-loaded macrophages treated with CXCL5 (Figure 3, D and E). Additionally, stimulation with CXCL5 induced ABCA1 expression in alternatively activated (M2) macrophages but not in classically activated (M1) macrophages (Figure 3G and Supplemental Figure 7, B and C). Accordingly, there is evidence to support that M2 macrophages are more susceptible to foam cell formation (16, 17). These observations suggest that in atherosclerotic lesions, in which macrophage heterogeneity is observed, several subtypes of macrophages can be targeted by CXCL5. Importantly, the induction of ABCA1 could be reversed, both by anti-CXCL5 Ab and by anti-CXCR2 Ab in cholesterol-loaded BMDMs. n = 4. (H) Cholesterol efflux was assessed in cholesterol-loaded PMs treated or not with CXCL5. n = 6. (I) Proposed mechanism of action for CXCL5 in atherosclerosis. EC, endothelial cell; Mac, macrophage. Data are mean ± SEM. *P < 0.05, **P < 0.01.
tion of an indirect pathway through cytokine release but rather suggests that the CXCL5/CXCR2 pathway regulates ABCA1 in a direct manner. Finally, we demonstrated that CXCL5 treatment produced an increase of cholesterol efflux in macrophages (Figure 3H). Altogether these data demonstrate that CXCL5 induces ABCA1 expression and reduces the cholesterol content of macrophages.

To summarize, our findings show that, unlike other ELR–CXCL chemokines (6, 7), the induction of CXCL5 plays a protective role in atherosclerosis (Figure 3I). It does so by limiting the cholesterol content of macrophages and therefore foam cell formation, a function that we believe has never been attributed to an ELR–CXCL chemokine prior to this study. These findings strengthen the emerging concept that chemokines can regulate foam cell formation, as was recently proposed for CXCL4 (19). Additionally, these findings highlight the complex interplay between inflammation and atherosclerosis and support the notion that proinflammatory mediators of acute immune responses are not necessarily harmful in chronic inflammatory diseases (20, 21). This study encourages us to rethink ELR–CXCL chemokines as important players of chronic inflammatory diseases, especially in light of their newly described role in macrophage regulation.

Methods
See Supplemental Methods for details.

Animal procedure. All mice were males on a C57BL/6 background. 6-week-old Apoe−/− and WT mice were placed on a WD (21% fat, 0.2% cholesterol, Harlan Teklad) or remained on CD for the indicated time (see the legends for Figures 1 and 2). ELR–CXCL chemokines were quantified from the aorta mRNA by qPCR, and plasma CXCL5 concentration was assessed by ELISA.

Additionally, Apoe−/− mice fed a WD were treated with a mouse CXCL5 mAb (50 μg per mouse, i.p., every 72 hours, R&D Systems; ref. 22) or IgG isotype control for 12 weeks. Alternatively, Apoe−/− BIR−/− and Apoe−/− BIR−/+ mice were fed a CD for 60 weeks. The brachiocephalic artery and heart were fixed with 4% PFA and embedded in paraffin for histology and immunostaining analysis. Blood was collected for measurement of leukocytes, lipids, cytokines, and chemokines.

In addition, Apoe−/− mice on WD were injected with CXCL5 (400 ng, i.p., every 72 hours, Peprotech). After 12 days, animals were sacrificed for peritoneal cell isolation. Macrophage foam cell formation was determined by flow cytometry and by staining of lipids with Oil Red O.

Cell stimulation. Using a cone and plate viscometer, HUVECs were exposed to steady unidirectional high (10 dyn/cm²) or low (2 dyn/cm²) LSS for 24 hours. Oxidized LDL (20 μg/ml, BTI) or IL-1β (10 ng/ml, Peprotech) was added for the last 4 hours or an additional 24 hours for treatment. PMs or BMDMs were stimulated with CXCL5 (100 ng/ml, Peprotech) and cholesterol loaded or not with acLDL (20 μg/ml, BTI). In some experiments, macrophages were also treated with CXCL5, CXCR2, IL-6, or control IgG Abs (20 μg/ml, 20 minutes prior to CXCL5 stimulation). qPCR analysis was performed after 4 hours of treatment. ELISA and Western blotting were performed on supernatant collected at 24 to 48 hours and on cell lysate collected at 24 hours. Macrophage foam cells were stained for lipids with Oil Red O.

Statistics. Data are expressed as mean ± SEM. Results were analyzed by 2-tailed Student’s t test or 1-way ANOVA with Bonferroni post-hoc test for multiple comparisons as appropriate using GraphPad Prism software. A P value of less than 0.05 was considered statistically significant.

Study approval. All experiments followed United Kingdom legislation for the protection of animals and were approved by the Ethical Review Process of Queen Mary, University of London.

Acknowledgments
This work was supported by Barts and the London Charity, European Union Seventh Framework Programme (Atherochemokine), and Deutsche Forschungsgemeinschaft (BA1374/13-2 and BA1374/16-1). J. Duchene was supported by the Marie Curie Actions (Intra-European Fellowship). We thank A. Rot (University of Birmingham, United Kingdom) for helpful discussions and A. Rigby (DFRZ, Berlin, Germany) for critical reading of the manuscript.

Received for publication August 27, 2012, and accepted in revised form December 17, 2012.

Address correspondence to: Johan Duchene, Max Delbrück Center for Molecular Medicine, Robert-Rössle-Straße 10, 13092 Berlin, Germany. Phone: 49.30.9406.3592; Fax: 49.30.9406.2110; E-mail: johan.duchene@mdc-berlin.de.